Dr. Frank van Leth
Home
Projects
Current
Previous
Publications
Talks
General Public
CV
Contact
Gunar Günther
Latest
Availability and costs of medicines for the treatment of tuberculosis in Europe
Rifapentine access in Europe: growing concerns over key tuberculosis treatment component
Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future.
Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
Relapse-free cure from multidrug-resistant tuberculosis in Germany
Time to revise WHO-recommended definitions of MDR-TB treatment outcomes
Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria
Treatment outcomes of MDR-TB and HIV co-infection in Europe
Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure
Treatment Outcomes in Multidrug-Resistant Tuberculosis
More on Treatment Outcomes in Multidrug-Resistant Tuberculosis
Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey
Multidrug-resistant tuberculosis in europe, 2010-2011
Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
Cite
×